Introduction Accumulating evidence suggests that glucagon-like peptide-1 (GLP-1) receptor agonists may have therapeutic effects against Parkinson’s disease (PD); however, clinical evidence has not yet ...
bDanish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital-Rigshospitalet, Glostrup, Denmark cDepartment of Neurology and Center of Clinical Neuroscience, First Faculty ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results